Published in Infect Immun on September 01, 2004
The frequency of BDCA3-positive dendritic cells is increased in the peripheral circulation of Kenyan children with severe malaria. Infect Immun (2006) 1.28
Macrophage-mediated but gamma interferon-independent innate immune responses control the primary wave of Plasmodium yoelii parasitemia. Infect Immun (2007) 1.19
Plasmodium strain determines dendritic cell function essential for survival from malaria. PLoS Pathog (2007) 1.12
Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 1.06
Malaria pigment paralyzes dendritic cells. J Biol (2006) 1.05
Plasmodium infection and endotoxic shock induce the expansion of regulatory dendritic cells. J Immunol (2008) 0.94
Dual effect of Plasmodium-infected erythrocytes on dendritic cell maturation. Malar J (2010) 0.91
Liver accumulation of Plasmodium chabaudi-infected red blood cells and modulation of regulatory T cell and dendritic cell responses. PLoS One (2013) 0.83
Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology (2006) 0.81
Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives. Rheumatol Int (2011) 0.81
Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology (2006) 0.79
Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria. J Infect Dis (2011) 0.78
Investigation of memory responses following Plasmodium chabaudi AS infection in mice distinct in susceptibility to clinical malaria. Parasitol Res (2009) 0.75
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol (2002) 4.64
Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature (1999) 4.28
Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol (2002) 3.74
The complexity of protective immunity against liver-stage malaria. J Immunol (2000) 2.92
Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest (2002) 2.55
The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38
Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol (1994) 2.31
Further checkpoints in Th1 development. Immunity (2002) 2.31
IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J Immunol (1995) 2.12
Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol (1998) 1.94
IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol (1999) 1.92
Immune effector mechanisms in malaria. Curr Opin Immunol (1999) 1.86
Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med (2003) 1.78
Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med (2001) 1.36
Direct activation of dendritic cells by the malaria parasite, Plasmodium chabaudi chabaudi. Eur J Immunol (2001) 1.33
Peripheral blood dendritic cells in children with acute Plasmodium falciparum malaria. Blood (2001) 1.29
Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol (2000) 1.29
Dendritic cells from malaria-infected mice are fully functional APC. J Immunol (2004) 1.19
The immunology of malaria infection. Curr Opin Immunol (2000) 1.19
Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol (2000) 1.18
Malaria, monocytes, macrophages and myeloid dendritic cells: sticking of infected erythrocytes switches off host cells. Curr Opin Immunol (2002) 1.16
Gamma interferon production is critical for protective immunity to infection with blood-stage Plasmodium berghei XAT but neither NO production nor NK cell activation is critical. Infect Immun (1999) 1.13
Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol (1997) 1.13
Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol (1998) 1.13
Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia (1999) 1.10
IL-12: the role of p40 versus p75. Scand J Immunol (2002) 1.09
The role of dendritic cell subsets in selection between tolerance and immunity. Immunol Cell Biol (2002) 1.05
Dendritic cells can initiate protective immune responses against malaria. Infect Immun (2001) 1.04
Modulation of host responses to blood-stage malaria by interleukin-12: from therapy to adjuvant activity. Microbes Infect (2001) 1.02
Antigen-presenting cell function during Plasmodium yoelii infection. Infect Immun (2002) 0.99
Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br J Cancer (2002) 0.95
Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer (2002) 0.94
Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol (2001) 0.92
Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J Clin Invest (2002) 0.91
Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med (2002) 0.89
Expansion of the CD4-, CD8- gamma delta T cell subset in the spleens of mice during non-lethal blood-stage malaria. Eur J Immunol (1993) 0.88
Immune regulation of protection and pathogenesis in Plasmodium falciparum malaria. Parassitologia (1999) 0.86
Selected problems of malaria blood stage immunity. Tokai J Exp Clin Med (1998) 0.84
Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther (2002) 0.83
Rapid diagnosis of malaria by use of fluorescent probes. Diagn Microbiol Infect Dis (1994) 0.80
Recent advances in dendritic cell vaccines for cancer treatment. J Dermatol (2001) 0.77
Killing of blood stage Plasmodium vinckei petteri by spleen macrophages through L-arginine dependent mechanism. Southeast Asian J Trop Med Public Health (1997) 0.77
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Pathogen recognition and development of particulate vaccines: does size matter? Methods (2006) 2.09
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine (2002) 1.97
IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nat Commun (2013) 1.71
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol (2004) 1.57
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films. Malar J (2008) 1.35
Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm (2007) 1.34
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res (2006) 1.33
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis (2008) 1.28
A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol (2009) 1.28
Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One (2008) 1.25
Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am J Trop Med Hyg (2003) 1.22
A regulatory role for CD37 in T cell proliferation. J Immunol (2004) 1.20
Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine (2006) 1.16
Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J Immunol (2006) 1.16
Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog (2009) 1.14
Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol (2009) 1.12
Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods (2006) 1.11
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol (2008) 1.10
Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol (2004) 1.09
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog (2009) 1.08
A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A (2003) 1.07
Defining target antigens for CD25+ FOXP3 + IFN-gamma- regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol (2007) 1.06
Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur J Immunol (2009) 1.05
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res (2006) 1.03
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology (2006) 1.03
Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. Angew Chem Int Ed Engl (2011) 1.02
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun (2002) 1.02
Round and round we go: cyclic peptides in disease. Curr Med Chem (2006) 1.01
Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am J Trop Med Hyg (2006) 1.00
Hot, sweet and sticky: the glycobiology of Plasmodium falciparum. Trends Parasitol (2008) 0.99
Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines (2008) 0.98
Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J Mol Biol (2002) 0.96
Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments. BMC Cancer (2012) 0.95
The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax (2012) 0.94
Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J Mol Biol (2002) 0.94
Reactive oxygen species level defines two functionally distinctive stages of inflammatory dendritic cell development from mouse bone marrow. J Immunol (2010) 0.93
Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses. Immunol Cell Biol (2005) 0.93
Cell-penetrating peptides: application in vaccine delivery. Biochim Biophys Acta (2009) 0.92
Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria. Infect Immun (2013) 0.92
Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection. Infect Immun (2009) 0.91
Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J Clin Invest (2002) 0.91
The adjuvanticity of a mannosylated antigen reveals TLR4 functionality essential for subset specialization and functional maturation of mouse dendritic cells. J Immunol (2008) 0.91
Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines (2008) 0.90
The challenge of assessing infant vaccine responses in resource-poor settings. Expert Rev Vaccines (2010) 0.90
Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J Med Chem (2005) 0.90
Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J Med Chem (2002) 0.90
Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors. J Gastrointest Surg (2008) 0.89
Dendritic cells: activation and maturation--applications for cancer immunotherapy. Curr Med Chem (2005) 0.89
Methods to measure T-cell responses. Expert Rev Vaccines (2010) 0.89
Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods (2013) 0.89
Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. Eur J Immunol (2006) 0.88
Structure and function of the myelin proteins: current status and perspectives in relation to multiple sclerosis. Curr Med Chem (2005) 0.88
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy (2013) 0.88
Systemic immune responses in sheep, induced by a novel nano-bead adjuvant. Vaccine (2005) 0.88
Insights into peptide-based vaccine design for cancer immunotherapy. Curr Med Chem (2005) 0.87
Selectively impaired CD8+ but not CD4+ T cell cycle arrest during priming as a consequence of dendritic cell interaction with plasmodium-infected red cells. J Immunol (2005) 0.86
A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J Immunol (2010) 0.86
A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses. J Neuroimmunol (2008) 0.86
The signalling imprints of nanoparticle uptake by bone marrow derived dendritic cells. Methods (2013) 0.86
Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines (2008) 0.85
The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert Opin Biol Ther (2008) 0.85
Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis. J Med Chem (2009) 0.85
Delivery of a heterologous antigen by a registered Salmonella vaccine (STM1). FEMS Microbiol Lett (2003) 0.84
Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.84
Structure and design of polycationic carriers for gene delivery. Mini Rev Med Chem (2006) 0.84
Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials (2008) 0.84
Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma. J Invest Surg (2013) 0.84
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol (2013) 0.84
Interleukin-13 regulates secretion of the tumor growth factor-{beta} superfamily cytokine activin A in allergic airway inflammation. Am J Respir Cell Mol Biol (2009) 0.83
Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol Pharm (2007) 0.83
Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. J Immunol (2013) 0.83
Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates. Chemistry (2012) 0.83
Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice. J Med Chem (2008) 0.83
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res (2013) 0.83
Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals. PLoS One (2012) 0.82
Characterization of blood monocyte phenotype in patients with endometrial cancer. Int J Gynecol Cancer (2012) 0.82
TNFR2 Expression on CD25(hi)FOXP3(+) T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors. Front Immunol (2013) 0.82
Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell Responses: IFN-Gamma Aids TLR Stimulation. J Drug Deliv (2013) 0.82
Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol (2013) 0.82
Simultaneous immunisation with a Wilms' tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice. Mol Immunol (2012) 0.82
Altered peptide ligands of myelin basic protein ( MBP87-99 ) conjugated to reduced mannan modulate immune responses in mice. Immunology (2009) 0.82
Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology (2006) 0.81